Dr. Robert W. Buckingham joined PHHS after having previously been appointed as the Jack W. Thompson, M.D. Distinguished Visiting Professor at the University of Michigan-Flint in 2013-14. A Yale graduate, Dr. Buckingham was appointed inaugural Executive Director/Dean of the School of Public Health with the University of Saskatchewan, in 2009. He has authored more than 12 books and many scientific referred papers, with the most recent being a textbook entitled, “A Primer on International Health” published by Allyn & Bacon, and five books on hospice care, including, “Care of the Dying Child” published by the Continuum Publishing Company, which was translated in seven languages.

Dr. Buckingham, helped pioneer the development of the first Hospice in the U.S. and is considered one of the “Founding Fathers” of hospice in North America. He was the first Director of Research of hospice in Connecticut in 1974, and subsequently founded another 81 hospice programs worldwide, including a hospice for children afflicted with HIV/AIDS in Thailand. Dr. Buckingham has developed new collaborative research and scholarly exchanged programs with Mahidol University in Thailand, Hawassa University in Ethiopia, as well as the Nelson Mandela Institute of Science and Technology in Arusha, Tanzania and locally, with the Heart and Stroke Foundation of Saskatchewan.

evin Galalae is the world’s foremost independent authority on the globalization-depopulation axis around which the international system has revolved since the inception of the United Nations in 1945, and the first to expose and scientifically demonstrate the existence, methods and consequences of the Global Depopulation Policy. He is the founder and Director of the Center of Global Consciousness (CGC), which is dedicated to the eradication of all covert chemical, biological, psychosocial and economic methods of population control and to their replacement with overt population control legislation through a global replacement level fertility law.

Biological and bacteriological methods, Causes and Consequences of the Global Depopulation Policy and Chemical and Biological Depopulation.

Head of the International UNESCO Chair on Sexual health and Human Rights, President of the Executive comittee, which decides for the political action and sexual health education at the UNESCO Chair and the UNITWIN network international

Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President Foundation de Beaumont Bonelli for Cancer Research.

Infectious Diseases

Dr. Mandy Hill has acquired a wealth of academic experience in the design, development, and implementation of behavioral research within a clinical setting. Trained as a clinical researcher, Dr. Hill has a documented history of advancing a prevention-based public health agenda within a clinical environment. Her academic portfolio to date has been based on creating a niche of merging public health and emergency medicine. She has published 22 peer reviewed manuscripts, 10 of which she first authored, in diverse areas addressing health disparities among disadvantaged minority populations, coupled with 25 abstracts, 20 presentations and extramural funding support from the Center for Disease Control and Prevention and the National Institutes of Health through the American Psychological Association and Centers for AIDS Research, as well as industry sponsored research. These tangible outcomes attest to her scientific contributions to date. Her primary research focus is HIV/AIDS, STIs, and STDs. In summary, here expertise includes the design, implementation, and analysis of pilot and exploratory studies, randomized clinical trial development and implementation, and integrating public health-based prevention research into routine clinical visits in the emergency department.

HIV/AIDS, STIs, and STDs

Marc H V Van Regenmortel is currently an Emeritus Research Director at the CNRS (French National Research Center) in the School of Biotechnology of the University of Strasbourg, France. He was for 22 years Director of the Immunochemistry Laboratory at the CNRS Molecular Biology Institute in Strasbourg and previously was a professor at several universities in South Africa and France. He served (1984-1990) as Vice Chairman and Chairman of the Virology Division of the International Union of Microbiological Societies (IUMS) and was Secretary General of IUMS from 1990 to 1999. He was also for six years (1996-2002) President of the International Committee on Taxonomy of Viruses. He supervised the research work of 30 PhD students and has published 400 research and review papers as well as 17 books in the fields of Virology and Immunochemistry. In 2009 he co-edited with Brian Mahy of the CDC in Atlanta, the third edition of the Encyclopedia of Virology in 5 volumes published by Elsevier. He is currently Editor-in-Chief of Archives of Virology, Journal of Molecular Recognition and Journal of AIDS & Clinical Research; An Associate Editor of Advances in Virus Research, Frontiers in Immunotherapies and Vaccines, Journal of Immunological Methods, ISRN Immunology and Bionomina.

General virology, Immunochemistry of viruses, viral diagnostics, synthetic peptide vaccines, HIV vaccines, SPR biosensors, viral taxonomy, philosophy of science

Dr. Kimberly A. Parker is an Associate Professor at Texas Womans University in Denton, TX. She has earned a PhD from the University of Georgias College of Public Health, a MPH from the Arnold School of Public Health at the University of South Carolina, and is a Master Certified Health Education Specialist. Dr. Parker conducts qualitative and mixed-methods research on women and minority health issues and currently serves as the Principle Investigator for several research projects. Her primary studies are Be-PrEPared, a curriclum development project to assess the implementation of a multi-strategies intervention to increase knowledge and awareness about PrEP among cis- and trans-women of color, Lend Us Your Voice Project, a qualitative study which examines the lived experience of HIV positive African American women in the South, and the HIV risk assessment study which examines multiple variables associated with contracting HIV, social vulnerabilities, and HIV risk perceptions among African American women. She has also spearheaded several public health curriculum design and evaluation projects related to HIV prevention and womens health issues. Dr. Parker has written several manuscripts on HIV/AIDS, the intersection of race and gender, and minority health issues, and has served as a guest columnist for the Dallas Morning News and The Body. Her research interest includes social sexual factors that influence HIV transmission and health disparities among vulnerable populations.

.

Dr Stef Stienstra is a Strategic and creative development manager in biomedical science, with a parallel career as a reserve commander of the Royal Dutch Navy. For the Dutch Armed Forces he has a responsibility in the counter measures in CBNRe threats and consequence management both in a military and in a civilian (terrorism) context. In his civil career he works internationally as consultant or as scientific supervisory board member for several medical and biotech companies. At this moment for MT-Derm in Berlin (D) developing a novel intradermal vaccination technology, IQ Therapeutics in Groningen (NL) developing therapeutic antibodies against anthrax and orthopox viruses, Hemacon in Düsseldorf (D) developing a field donor blood separation and blood transfusion unit, Infection Control in Eemnes (NL) developing a bio-disinfection system for bioterrorism consequence management and IB Consulting in The Hague (NL) for biodefense projects. He has finished his studies Medicine and Biochemistry in The Netherlands and has extensive practical experience in cell biology, immuno-haematology, biodefense and transfusion medicine. His natural business acumen and negotiation competence helps to initiate new successful businesses, often created out of unexpected combinations of technologies. His good understanding of abstract science combined with excellent skills in the communication of scientific matters to non-specialists, helps him with strategic consulting at top level management.

CBRN defense, (therapeutic) vaccines, trauma healthcare, blood transfusion, sailing

Timms is Professor of Microbiology and Director of Research at QUT’s Institute of Health and Biomedical Innovation in Brisbane Australia. He is a nationally and internationally renowned microbiologist with specific expertise in the area of Chlamydia. His laboratory is acknowledged as the leading Australian laboratory and one of the leading groups internationally working on all aspects of chlamydial infections. Timms has published over 170 refereed journal papers and is editor of the journal, Pathogens and Disease.

He leads a well established research team of 10 people. His research group is developing vaccines and new diagnostics for chlamydial diseases in humans and animals as well as an improved understanding of chlamydial genomics, cell biology and pathogenicity. The group is widely acknowledged for its major contributions to chlamydial infections in koalas and other wildlife, including the development of a vaccine for koalas.

Kevin Galalae is the world’s foremost independent authority on the globalization-depopulation axis around which the international system has revolved since the inception of the United Nations in 1945, and the first to expose and scientifically demonstrate the existence, methods and consequences of the Global Depopulation Policy. He is the founder and Director of the Center of Global Consciousness (CGC), which is dedicated to the eradication of all covert chemical, biological, psychosocial and economic methods of population control and to their replacement with overt population control legislation through a global replacement level fertility law.

covert chemical, biological and bacteriological methods, Causes and Consequences of the Global Depopulation Policy and Chemical and Biological Depopulation.

Enric Pedrol is from Fundació Sant Hospital Infectious Diseases, Internal Medicine (General Medicine), Spain

Infectious Disease, Medicine, HIV, Infection, AIDS, Hepatitis C, Liver, Hepatitis Viruses

Daniel Bauer is internationally revered as the Successor to the legendary escape artist Harry Houdini and globally respected as a 12-year warrior and survivor living with HIV/AIDS. Through heart-breaking loss, such as burying his baby brother who passed from AIDS-related complications, to conquering impossible moments of rare survival, he has gracefully triumphed to once again pursing his dreams. He is one the most requested motivational public speakers and entertainers who continues to present highly engaging educational experiences and spectacularly, life-changing theatrical productions to tens of thousands annually (adolescents, healthcare professionals and mainstream communities &audiences at-large) focusing on topics such as living with HIV/AIDS, prevention, reversing HIV/AIDS-related man-made stigma and so much more. He is the current active celebrity voice and face of JustGetTested.com. He continues to work tirelessly to promote equality for all living with and/or affected by the global HIV/AIDS pandemic. His work as both an escape artist and speaker have been featured on: National Television Networks [NBC, CBS, ABC and FOX], International print/radio media (i.e. poz.com/blogs, positivelite.com, NPR Radio, Poz I Am Radio Show),International Theatrical Stages including New York City off-Broadway; and has been highlighted at internationally revered events such as The OMICS Group2013 International HIV/STI Conference, The National Healthy Living Summit, 2012 International AIDS Conference (AIDS Reunion Program, Washington, D.C.), The 2013 University of Minnesota African Student Association Red Spots Gala, and The Texas State-wide HIV/HEI Conference.

HIV

Charbell Miguel Haddad Kury, a Medical Doctor and Professor of Medicine, graduated from the Medical School of the Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil in 2003. He is expert in Public Health, from the Medicine School of Campos dos Goytacazes, in 2004. He is Pediatrician infectious disease specialist from the Jesus Hospital, Rio de Janeiro in 2007. He is also a Professor of Pediatrics of the Medicine Schools of Campos dos Goytacazes and the Federal University of Rio de Janeiro, Brazil. He has a Master’s degree in Applied Microbiology and Parasitology from the Fluminense Federal University, in 2013. He is a Pediatrician and Neonatologist of the St. John the Baptist Hospital, Municipality of Macaé, State of Rio de Janeiro, Brazil, since 2005 and Coordinator of Immunization and Health Surveillance of the Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil, since 2009. He did research on immunization programs, once the municipality of Campos dos Goytacazes implemented the largest immunization program.

Public Health,HIV/AIDS

Hiroshi Ohrui has received Ph.D. degree (1971) from The University of Tokyo. He joined RIKEN (1966), moved to Tohoku University (1881) and then to Yokohama University of Pharmacy (2006). His interest covers Organic Synthesis, Chemical Biology, and Chiral Discrimination.

HIV

Dr. NWAKO Okechukwu Francis had his B.Sc in Applied Microbiology(upper credit ) in 2001 and proceeded to Medical School where he graduated in 2009. In 2012, he obtained his M.Sc( Medical Microbiology) and has completed his Ph.D course work in Medical Microbiology with major in Mycology. He hope to complete his research work by 2016. He obtained his Primary in Internal Medicine in 2010 and became a specialist in Internal Medicine in 2015 from the West Africa College of Physicians. He has published several original articles in international journals and has attended several conferences both locally and internationally including the famous HIV/AIDS 2013 organized by OMICS conferences. He has reviewed many articles for British Journal of Medicine and Medical Research and Journal of AIDS.

HIV

Daniel Bauer is internationally revered as the Successor to the legendary escape artist Harry Houdini and globally respected as a 12-year warrior and survivor living with HIV/AIDS. Through heart-breaking loss, such as burying his baby brother who passed from AIDS-related complications, to conquering impossible moments of rare survival, he has gracefully triumphed to once again pursing his dreams. He is one the most requested motivational public speakers and entertainers who continues to present highly engaging educational experiences and spectacularly, life-changing theatrical productions to tens of thousands annually (adolescents, healthcare professionals and mainstream communities &audiences at-large) focusing on topics such as living with HIV/AIDS, prevention, reversing HIV/AIDS-related man-made stigma and so much more. He is the current active celebrity voice and face of JustGetTested.com. He continues to work tirelessly to promote equality for all living with and/or affected by the global HIV/AIDS pandemic. His work as both an escape artist and speaker have been featured on: National Television Networks [NBC, CBS, ABC and FOX], International print/radio media (i.e. poz.com/blogs, positivelite.com, NPR Radio, Poz I Am Radio Show),International Theatrical Stages including New York City off-Broadway; and has been highlighted at internationally revered events such as The OMICS Group2013 International HIV/STI Conference, The National Healthy Living Summit, 2012 International AIDS Conference (AIDS Reunion Program, Washington, D.C.), The 2013 University of Minnesota African Student Association Red Spots Gala, and The Texas State-wide HIV/HEI Conference.

HIV

Baran Halina is presently Head of the Karl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, Lower Austria, from 2005-2011 she was the head of Head of the Neurochemical Laboratory Karl Landsteiner Institute Mauer and Head of Neurophysiology, Veterinary Medical University Vienna. In the year 1998-2005, she was Assoc. Prof. at Institute of Pharmacology and Toxicology, Veterinary Medical University Vienna.

HIV

Michelle Moorhouse graduated from Wits University in South Africa, and qualified as a GP anaesthetist. Then, like many of her peers, switched her professional track to the management of HIV. Michelle co-founded Triple M Research, placing Port Elizabeth firmly on the map as one of the first HIV clinical trial centers in the Eastern Cape. Michelle went on to found the HIV journal club in PE, which later became the local chapter of the Southern African HIV Clinicians Society. In 2003 Michelle was awarded an Honorary Clinical Fellowship at the Royal Free Hospital in London. She has also worked in the pharmaceutical industry, holding senior advisory posts at Abbott and Boehringer, she led the UK launch of Tipranavir in 2005, and was medical director at Novartis Vaccines and acting head of HIV therapeutics at GSK. Whilst working in the UK, Michelle earned the respect of many leading internationally renowned HIV clinicians. Michelle returned to South Africa in 2007, where she re-established her general/HIV practice - much to the excitement of a number of patients who started ARV treatment under her management many years earlier! Michelle went on to found a research centre that focused on HIV clinical trials, and also provided principle investigator services to local CROs. Consulting at a local clinic in Motherwelltownship for IYDSA, an Eastern Cape based NPO, signaled a change in Michelle’s career. This branch of public health brought her closer to the other realities of the HIV/AIDS epidemic, providing an opportunity to play a greater part in tackling the disease that she has dedicated her career to so passionately. She later joined full-time, initially as Clinical Advisor, and then Technical Lead Research and Training, proudly contributing to the NGO's rapid growth, rebranding to Beyond Zero, and becoming one of the leading HIV/AIDS focused NPOs in the Eastern Cape. In 2012, Michelle was elected to the inaugural Board of Directors of the Southern African HIV Clinicians Society, devoting much of her time to organisational development, supporting new treatment guidelines, conceptualising a new corporate membership programme, and of course, a little bit of activism against HIV/AIDS quackery(!), and supporting the biennial Clinicians Society Conference She is also member of the Editorial Boards of HIV Nursing Matters magazine, and the MRC AfroAIDSinfo portal, as well as a member of MedDigital Expert Panel and HIV Physicians Panel. In September 2014, Michelle took up an exciting position as Senior Clinician at Wits Reproductive Health and HIV Institute (RHI), and relocated to Johannesburg. In this role, she is actively engaged in clinical work, research and teaching, as well as sitting on National HIV guideline committees, advising the National Department of Health, training the master trainers of the 9 provinces on new guidelines, to mention a few of her responsibilities. Michelle has recently been appointed to the national Third Line ART Committee, which reviews patients failing their second line regimen (or beyond) and advises regarding their further management for the National Department of Health. Michelle is particularly interested in ARV resistance, helping HIV affected couples have healthy babies, and sharing her HIV knowledge through talks, workshops and training.

HIV

Bernardino Geraldo Alves Souto was graduated in medicine at Federal University of Juiz de Fora, Minas Gerais, Brazil, in 1987. Received his master's degree in 2002 and Ph.D. in 2006, in Infectious Diseases and Tropical Medicine, at Federal University of Minas Gerais, Brazil. Specialist in Intensive Care Medicine, Clinical Medicine/Internal Medicine and Epidemiology. Professor of the Department of Medicine of the Federal University of São Carlos, São Paulo, Brazil. Practices general integral medicine and is attending physician at Specialized Care Service in STD/HIV/Aids of São Carlos, São Paulo, Brazil. As researcher, mainly investigates the epidemiology of HIV infection, and the psychological and social issues related to people living with this virus.

HIV/AIDS

Charbell Miguel Haddad Kury, a Medical Doctor and Professor of Medicine, graduated from the Medical School of the Municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil in 2003. He is expert in Public Health, from the Medicine School of Campos dos Goytacazes, in 2004. He is Pediatrician infectious disease specialist from the Jesus Hospital, Rio de Janeiro in 2007. He is also a Professor of Pediatrics of the Medicine Schools of Campos dos Goytacazes and the Federal University of Rio de Janeiro, Brazil. He has a Master degree in applied microbiology and parasitology from the Fluminense Federal University, in 2013. He is a Pediatrician and Neonatologist of the St. John the Baptist hospital, municipality of Macaé, State of Rio de Janeiro, Brazil, since 2005 and Coordinator of Immunization and Health surveillance of the municipality of Campos dos Goytacazes, State of Rio de Janeiro, Brazil, since 2009. He did research on immunization programs, once the municipality of Campos dos Goytacazes implemented the largest immunization program in early 2009.

HIV

D K Agarwal has 24 years of experience in the field of Nephrology including specialization in renal transplant, hemodialysis, CAPD and all kidney problems and diseases along with critical kidney patients with emergency management. He is well experienced in handling kidney patients with diabetes and hypertension and other diseases. He is also well experienced in renal transplantation in HIV patients. He worked as Senior Consultant, Nephrologist in various institutions of National and International repute like Nizam’s Institute of Medical Sciences, Hyderabad, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow etc. He isexperienced at division of Nephrology, Department of Medicine, University of Missouri, School of Medicine, Columbia, USA. At present he is working as Senior Consultant in Nephrology and renal transplant, Indraprastha Apollo Hospitals, New Delhi, India.

HIV/AIDS

Nwako Okechukwu Francis is a registrar in medicine department of Federal medical centre Owerri and a medical microbiologist with about 3 years teaching experience. He obtained B.Sc in microbiology in 2001, MBBS in 2009, primary fellowship in 2010 and M.Sc in medical microbiology in 2012. He has done some published work Nigeria. His on the job experience in the care and management of HIV positive clients in a resource poor setting ignited his interest in HIV medicine. His keen interest is in opportunistic infections in HIV/AIDS. He has applied to study Infection and Immunity in Ph.D in Nigeria. He is a member of NMA, associate fellow of WACP, associate fellow of NPMC, member NSM and NARD.

HIV

Dr. Farshad Guirakhoo, a virologist by training, was named one of the 50 Most Influential People in Vaccines in VaccineNation’s 2014 list. His most recent assignment was CTO at Vaxess Technologies. Prior to this, he served as CSO at Hookipa Biotech and Executive Director of External R&D at Sanofi Pasteur. Before joining Sanofi Pasteur in 2007, he was with Acambis for 15 years as Head of Research and co-invented the ChimeriVax-technology platform in association with St. Louis University. This platform has successfully been applied in the development of vaccines such as IMOJEV™, PreVenile™, Dengvaxia™, and WN human vaccine. Dr. Guirakhoo has broad experience in the application of gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies, and attenuated viral vectored vaccines for the prevention and treatment of infectious diseases. Dr. Guirakhoo is the author of over 80 peer-reviewed publications and holder of multiple patents.

Application of genetics, gene expression technologies and molecular virology for the constructions and productions of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases.

Dr Kedzierska trained as a viral immunologist and has over 14 years of experience in researching the immune responses to acute (influenza) and chronic (HIV) viral infections. Her expertise in both the murine system and human settings allows her to translate any of the key findings obtained from an easily manipulated mouse model into human viral immunology. Her PhD work undertaken at the Burnet Institute in Melbourne has provided an important contribution to our knowledge of AIDS pathogenesis by proposing the mechanisms of why HIV-infected patients develop specific opportunistic infections as their disease progresses, ultimately the cause of their death. Her PhD work was recognised by prestigious awards, including a 2001 Premier’s Commendation for Medical Research, 2002 Monash University Mollie Holman Doctoral Medal for the Best PhD Thesis and the NHMRC Peter Doherty Postdoctoral Fellowship to pursue her postdoctoral research with Nobel Laureate Professor Peter Doherty. She joined Professor Doherty’s laboratory upon his return to the Department of Microbiology and Immunology at the University of Melbourne in July 2002. During the four-year postdoctoral position she has further contributed to the field of viral immunology and developed her own research interests related to the cellular and molecular aspects of CD8+ T cell immunity to influenza virus infection. After being awarded the NHMRC RD Wright Fellowship and a NHMRC Project Grant, she established her independent research group in the Department of Microbiology and Immunology. She aims to understand how immunological T cell memory is generated, whether it is feasible to elicit immunity towards escape viral variants, and how T cell receptor repertoire relates to T cell phenotype, function and viral escape.

Viral immunology, T cell memory formation, influenza (Immunology).

Dr. Barakat is an Assistant Professor at the school of Pharmacy at the University of Alberta, Canada. His research stands at the multidisciplinary interface of physics, biology and computer science. Dr. Barakat’s major focus is on developing and applying state-of-the-art computational drug discovery tools to discover new antiviral and immunotherapeutic drugs. Dr. Barakat has made great contributions in understanding the nature and biophysical processes underlying protein–drug, protein–protein and drug off-target interactions and predicting drug-mediated toxicity. He also received numerous awards including the CIHR and AIHS postdoctoral fellowships, the prestigious University of Alberta dissertation award and many distinction awards throughout his undergraduate and graduate studies. Dr. Barakat is also the editor of the Journal of Pharmaceutical Care & Health Systems and serves as a guest reviewer for several journals.

Host Immune Defences & Immunotherapy

Hiroshi Ohrui was born in 1942. He received his B.S. (1965) and Ph.D. degrees (1971) from The University of Tokyo under the direction of Professor Masanao Matsui. He joined RIKEN in 1966 as a researcher. In 1981, he moved to Tohoku University as Associate Professor in the Department of Food Chemistry, Faculty of Agriculture. In 1977, he was promoted to Full Professor, Graduate School of Life Science. In 2006, he moved to Yokohama University of Pharmacy as Professor. He worked for Dr. J. J. Fox at Sloan Kettering Institute for Cancer Research (1972-1973) as a Research Associate, and for Dr. J. G. Moffatt at Syntex Research (1973-1974) as a postdoctoral fellow. He worked for The Technical University of Darmstadt as an invited professor by DAAD (1990). He has received several awards including The Agricultural Society of Japan Award for Young Scientists (1974), Inoue Prize for Science (2001), Japan Prize of Agricultural Sciences (2004), The Japan Society for Analytical Chemistry Award (2004), and The Japan Academy Prize (2010).

His research interests cover organic synthesis, chemical biology, and chiral discrimination.

To be Updated

Virus Cell Interaction. The African swine fever virus model

To be updated

Infectious Diseases, Internal Medicine

To be Updated

Microbiological Studies

Dr. Keivan Zandi completed his Ph.D in Medical Virology from Tarbiat Modarres University, Iran. He is currently working as an associate professor in Department of Medical Microbiology, University Malaya. He has published more than 60 research papers in various Scientific Journals and has several patents on his name. He is actively severing as an Editorial Board Member for Scientific Reports with Nature publishing group as well as several other journals such as International Journal of Virology, SM tropical Medicine Journal, International Journal of Pharmacology, American journal of Drug Discovery and development, International Journal of Drug Discovery and Biotechnology journal.

Medical Microbiology

Professor Ludmila Viksna is one of the most experienced experts in Infectology and Hepatology in Latvia. She is Chief Specialist of Infectology in Riga East Clinical University Hospital, Chief Infectologist of Ministry of Health of the Republic of Latvia, Head of the Department of Infectology and Dermatology in Riga Stradins University, Corresponding Member of Latvian Academy of Sciences and President of Association of Infectologists and Hepatologists of Latvia. Professor L.Viksna is the author of 5 books, more than 300 publications and she holds 15 patents.

Hepatitis, Tuberculosis and Borreliosis.

Dr. Edmond Puca has received his PhD in University Hospital Center Mother Teresa during the period of 2010-2014. Currently, he is working as infectologue in University Hospital Center “Mother Teresa”.He is a member of Albanian Society of infectology.He is serving as an editorial member as well as reviewer for several reputed journals.

His research includes sepsis, HFRS and leptospirosis

Associate Professor Angelika Krumina is PhD of Medical Sciences, Leading Researcher in Infectology field in Riga East Clinical University Hospital. A.Krumina is Scientific Expert of Latvian Academy of Sciences, Board Member of Latvian Medical Association and Member of European Society of Clinical Microbiology and Infectious Diseases. During 2011-2012 she was Project Coordinator in State Programme of Latvian Academy of Sciences. Currently she is Work Package 6 leader in Latvia of Baltinfect project of the Seventh Framework Programme (FP7) of the European Commission.

Her major scientific interests are Human herpes viruses HHV- 6 and HHV-7 and Vector - borne infectious diseases.

Sunil Kumar Gupta has completed his PhD at the age of 32 years from King George\'s Medical University, Lucknow, INDIA. He is the Research Scientist of Bioinformatics, a premier Biotech Park, Lucknow India. He has published more than 12 papers in reputed journals and presented more than 15 research findings in National and International conferences.

His Research interest is in the area of infectious diseases specially on Genus Flavivirus.

C. Yong Kang has completed his PhD from McMaster University in Canada and post-doctoral training at the University of Wisconsin-Madison. He served as a Professor of Virology at the University of Texas Southwestern Medical School, Professor and Chairman at the University of Ottawa Faculty of Medicine, and Dean of Science at the University of Western Ontario. He has published 137 peer reviewed research papers and 151 scientific proceedings and abstracts. He holds nine international biotechnology patents. He received numerous awards including the Ho-Am Prize in Medicine. He is a Life-time Fellow of the Royal Society of Canada Academy of Science. He serves as a reviewer for eight international journals.

His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome.

DC Tang is the Founder of VaxDome LLC and Vaxin Inc. He was a pioneer during the development of DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology. He was selected as a Distinguished Overseas Scientist by the South Korea KOFST Brain Pool Program; subsequently joined Chung-Ang University and International Vaccine Institute in Seoul; and was appointed as a Scientist at IVI after the Brain Pool Program Award expired in 2013. He founded VaxDome LLC in Birmingham, Alabama, USA in 2014 and moved the company to Dallas, Texas, USA in 2015.

DNA vaccines, noninvasive skin-patch vaccines, adenovirus-vectored vaccines, and the protective innate-adaptive immunity duo platform technology

Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Law”, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem” for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.

Virology

Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology

Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.

Since 2005 - a CSO at XENOTOX, Inc. Have a medical background (M.D., 1970), Ph.D. in Biochemistry (1973), D.Sc. in Molecular Toxicology (1983). Hold progressively responsible positions: Group Leader (74-79), Head of the Laboratory (1979-87), Department Chair (1987-91), all at Russian Academy of Science. In the US: a Senior Scientist at NCI, NIH (1991-95), Professor (since 2010 - visiting) at Mount Sinai School of Medicine (1995-to date). Author of 5 monographs and 250+ peer reviewed publications. By using enzyme-kinetic and inhibitory analyses, pioneered in revealing TCDD-induced CYP1B1 (FEBS Letters, 1987). Invented the recombinant and TCDD-induced microsomal and isolated monooxygenase isoforms CYP1A1 and CYP1A2, to study regulatory effects of bioflavonoids on procarcinogens metabolism in humans (BBA, 1994). Since the discovery of trans-activation effect of TCDD on HIV-1 (BBRC, 1991), have established Xenobiotical Virology, a biomedical discipline dealing with mechanisms of dioxin effects on DRE-containing genes of human viruses, transcription factors and cytokines linked to inflammation and malignancy pathways.

Viruses

Sita Awasthi has received her Ph.D in Biochemistry from Devi Ahilya University at Indore, India and her postdoctoral training from University of Pennsylvania at Philadelphia. Currently she is a Research Assistant Professor at University of Pennsylvania, Pearlman School of Medicine, Infectious Disease Division. Her research interests are HSV-2 vaccine development against genital herpes disease and HSV-2 HIV-2 co-infections. She has published numerous research articles and serving as an editorial board member of Journals of antivirals and anti retrovirals, Journal of Immunoassay and Immunochemistry.

HIV and Different Viruses

Walter Doerfler has completed Munich Medical School (LMU), Doctor of Medicine thesis in Anatomy and Internships in Munich and Trenton, NJ, USA. He did his Postdoctoral studies in Molecular Genetics at the Max-Planck-Institute for Biochemistry in Munich and in the Department of Biochemistry, Stanford University Medical School.

Genetics and Molecular Virology

Zhanglei has completed her PhD at the age of 30 years from Heping Campus Jilin University. Now she is a associate professor and postgraduate tutor of institute of Special Wild Economic Animals and Plants, Chinese Academy of Agricultural Sciences. Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Mainly engaged in fur animal disease including molecular epidemiological investigation and diagnosis products research work

Marcin Sieńczyk graduated from the Molecular Biotechnology and Biocatalysis program in 2002 at Wroclaw University of Technology, four years later he obtained his PhD in Medicinal Chemistry. In 2015 he was awarded habilitation (DSc) in Biotechnology. He currently holds the position of assistant professor at Wroclaw University of Technology, Division of Medicinal Chemistry and Microbiology. His research is focused on the development of low molecular weight compounds designed to target proteases involved in the pathogenesis of various diseases including cancer, bacterial and viral infections. Work in his laboratory also generates antibodies to be used in the development of new diagnostic assays for human diseases. He is a co-author of more than 40 papers, 14 patents and more than 25 pending patent applications.

Viruses

Dr.Zenab Torky is an Assistant Professor of Microbiology in the department of Microbiology, Faculty of Science, Ain Shams University, in Egypt. She also worked as a Visiting Scientist in the department of Biological Sciences, University of Louisville, USA. Dr.Zenab has also reviewed and edited many papers for the Food Safety Journal, and participated in two projects with members of the Remold laboratory in University of Louisville, to study the nature and conditions of adaptations of vesicular somatitis virus to a cancer cell line, using molecular biology techniques like genome sequencing and phenotypic characterization of recombinant viruses, to design oncolytic viruses that kill cancer cells, and sampling, genotypic and phenotypic characterization of Pseudomonas bacteria species isolated from human homes, and their pets.

Dr.Zenab’s main research interest is finding a way to protect living cells from viral infection, by studying ways to strengthen the immunity of the host by using natural compounds like antivirals, and studying their effect on viral replication.

Girish J. Kotwal, received his Ph.D. from the Biochemistry department, McMaster University, Canada in 1985. He did his post doctoral work at the National Institutes of Health (NIH) in Bethesda, MD, USA in the Laboratory of Viral Diseases from 1984-1990 and co-discovered the vaccinia virus complement control protein (VCP) along with Dr. Bernard Moss, member of the US National Academy of Science (NAS). During the 90s he established a structural biology program which included overexpression of VCP, a heavily disulphide bonded protein and directed the preclinical program to evaluate the therapeutic potential of VCP. In 2002 he founded Kotwal Bioconsulting, LLC, in 2004 he founded kbiotech pvt. ltd., in South Africa, in 2005 he co-founded InFlaMed Inc. in USA. In 2010 he assisted in founding Icelandic Cardio Pharma (IceCP) in Iceland. He is currently Professor of Biochemistry and Microbiology at UMHS, WI, Adjunct Professor of Medicine, UMass medical school, Worcester, MA and Adjunct Professor of Traditional Chinese Medicine at Henan University, China. He has authored over 100 publications, 97 of which are found on pubmed.

Medical Microbiology, Dental Microbiology and Immunology, Cellular and Molecular Immunology, Intracellular signaling mechanisms in lymphoid cell activation, Cytolytic mechanisms of CTLs and NK cells, Complement pathways & complement regulatory proteins, Immune responses against tumors, Mechanisms of apoptosis in the immune system, transgenic and knockout mice, Modern vaccine design & immunization, HLA & TCR genes in autoimmunity, cellular and molecular mechanisms of autoimmunity, Fundamental Virology, Molecular Virology,

Dominic Targema Abaver has completed his Ph.D.at the age of 40 years from University of Abuja in parasitology; He is chief superintendent of Immigration Nigerian Immigration service, a paramilitary organization in the ministry of interior. He has published number of papers on HIV/AIDS, Immunology and parasitology in reputed journals, such as African Health Science, Pakistani Journal of Medical sciences, African Journal for Physical, Health Education, Recreation and Dance (AJPHERD). He is a member of Nigerian society of parasitology and a fellow, Institute of Cooperate Administration. Currently, D.T. Abaver is a Contract Researcher at Walter Sisulu University, Eastern Cape, South Africa. His research interest include Epidemiology of HIV/AIDS and other Opportunistic Infections; Preventive measures/techniques of HIV/AIDS; gender, age and sexual orientation as determinants for the impact of HIV/AIDS

HIV/Aids

Dr Benani is a responsible of Molecular Biology Laboratory at Pasteur Institute of Morocco this laboratory is a national reference laboratory for Hepatitis C Program (Moroccan ministry of health). He is also the elect-president of Arab Society for Virology and Active member on the Advisory Board, Consultative Meeting on Regional Strategy for Prevention and Control of Viral Hepatitis and Other Epidemics-Prone Blood-Borne Diseases, in 2008 (WHO/EMRO, Cairo, Egypt). He got his master of molecular biology and biotechnology at Université Libre of Bruxelles (ULB, Belgium) and his PhD in molecular microbiology in Fes University (Morocco). He participates in several international and national workshops and congresses. He is also implicated in student’s research for their training, master, and PhD. He published in several journals including journal of medical virology, BMC public health, Virology Journal, He is an active researcher in molecular epidemiology of HBV and HCV in general population and high Risk groups in Morocco. He organized the 1st International Symposium for Virology in Morocco in 2003 (Marrakech, Morocco) and the First PCR Forum and Molecular Typing at Pasteur Institute of Morocco

Molecular epidemiology of HBV and HCV

Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology

Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.

Dr. Chen currently is the Deputy Director of Alaska State Public Health Virology Laboratory and an Associate Professor in the Department of Biology and Wildlife and Institute of Arctic Biology at the University of Alaska Fairbanks. Dr. Chen's research activity focuses on the diagnosis and research of public health related viral infection in Alaska. His Virology Laboratory is a joint effort between State of Alaska Public Health Division and University of Alaska Fairbanks. Current research projects involve both clinical and basic virology research. Dr.Chen obtained his Ph.D. Degree in Virology at Osaka University Medical School in Japan and his post doctorate training at University of British Columbia at Vancouver, Canada.

The clinical research focuses on molecular diagnosis of viral infections, as well as technology development for the diagnosis of emerging human pathogens. The basic research in this lab involves in the virus-human cell interaction and the role of tumor virus in human tumorigenesis.

Girish J. Kotwal, received his Ph.D. from the Biochemistry department, McMaster University, Canada in 1985. He did his post doctoral work at the National Institutes of Health (NIH) in Bethesda, MD, USA in the Laboratory of Viral Diseases from 1984-1990 and co-discovered the vaccinia virus complement control protein (VCP) along with Dr. Bernard Moss, member of the US National Academy of Science (NAS). During the 90s he established a structural biology program which included overexpression of VCP, a heavily disulphide bonded protein and directed the preclinical program to evaluate the therapeutic potential of VCP. In 2002 he founded Kotwal Bioconsulting, LLC, in 2004 he founded kbiotech pvt. ltd., in South Africa, in 2005 he co-founded InFlaMed Inc. in USA. In 2010 he assisted in founding Icelandic Cardio Pharma (IceCP) in Iceland. He is currently Professor of Biochemistry and Microbiology at UMHS, WI, Adjunct Professor of Medicine, UMass medical school, Worcester, MA and Adjunct Professor of Traditional Chinese Medicine at Henan University, China. He has authored over 100 publications, 97 of which are found on pubmed.

Medical Microbiology, Dental Microbiology and Immunology, Cellular and Molecular Immunology, Intracellular signaling mechanisms in lymphoid cell activation, Cytolytic mechanisms of CTLs and NK cells, Complement pathways & complement regulatory proteins, Immune responses against tumors, Mechanisms of apoptosis in the immune system, transgenic and knockout mice, Modern vaccine design & immunization, HLA & TCR genes in autoimmunity, cellular and molecular mechanisms of autoimmunity, Fundamental Virology, Molecular Virology,

C. Yong Kang has completed his PhD from McMaster University in Canada and post-doctoral training at the University of Wisconsin-Madison. He served as a Professor of Virology at the University of Texas Southwestern Medical School, Professor and Chairman at the University of Ottawa Faculty of Medicine, and Dean of Science at the University of Western Ontario. He has published 137 peer reviewed research papers and 151 scientific proceedings and abstracts. He holds nine international biotechnology patents. He received numerous awards including the Ho-Am Prize in Medicine. He is a Life-time Fellow of the Royal Society of Canada Academy of Science. He serves as a reviewer for eight international journals.

Professor Jun-Wen Li, doctoral supervisor at institute of Health and Environmental Medicine, is the academic leader of environmental hygiene. He was appointed as a visiting scholar to the Water Research Centre, University of New South Wales in the Australia (2006.9-2007.9) because of his outstanding work. His research has been supported by more than 20 foundation-programs. He has published more than 20 papers in reputed journals and has been serving as an editorial board member of many journals.

His major interests are microorganisms detection technology in water and food, disinfection of drinking water and safety evaluation for recycle water.

Dr. Yefei Zhu, is the Deputy Chief and Team Leader for the outbreak response team in the Department of Acute Infectious Diseases Outbreak Response and Prevention, Jiangsu Provincial Center for Disease Control and Prevention in China. During his 8 years with the Jiangsu CDC, He received his M.D. degree from Nanjing Medical University, Nanjing, China in 2006. He was certified as professor Jiangsu Province Science and Technology Department, Nanjing, China in 2014. His research interests draw on the interplay between epidemiology and public health. His research has focused on the epidemiology of infectious diseases, with recent emphasis on molecular and geographic applications in Jiangsu, China. His research involves extensive collaboration with colleagues from other disciplines, including microbiology, geography, public health, climate change, et al.

Dr.Zhu focused his efforts on investigating outbreaks of human illnesses caused by pathogens, including E coli O157:H7, norovirus, avian influenza (H7N9) virus, et al.

Dr. Narasaiah Kolliputi is an Associate Professor and Division Director of Research Education for Division of Allergy and Immunology at the Morsani College of Medicine. Kolliputi is working on translational strategies to attenuate oxidative stress mediated acute lung injury (ALI) and pulmonary fibrosis. He received his postdoctoral training in the Massachusetts General Hospital, Harvard Medical School. Kolliputi is currently serving as a grant reviewer for the National Institute of Health, Department of Defense and American Heart Association Grants. He is an Associate Editor for Frontiers in Pharmacology, Frontiers in Physiology, Frontiers in Genetics and Guest Associate Editor for Frontiers in Mitochondrial Physiology, Editorial Board Member for Translational Medicine, Virology & Mycology and Journal of Biocatalysis & Biotransformation. Dr. Kolliputi’s research is funded by NIH RO1 and American Heart Association Scientist Developmental grants.

Pathogen-Associated Molecular Patterns (PAMPs) and Danger-Associated Molecular Patterns (DAMPs); Viral and fungal infections of the lung; pulmonary hemorrhage syndrome associated with dengue fever; and Lung injury.

Dr. Barakat is an Assistant Professor at the school of Pharmacy at the University of Alberta, Canada. His research stands at the multidisciplinary interface of physics, biology and computer science. Dr. Barakat has made great contributions in understanding the nature and biophysical processes underlying protein–drug, protein–protein and drug off-target interactions and predicting drug-mediated toxicity. He also received numerous awards including the CIHR and AIHS postdoctoral fellowships, the prestigious University of Alberta dissertation award and many distinction awards throughout his undergraduate and graduate studies. Dr. Barakat is also the editor of the Journal of Pharmaceutical Care & Health Systems and serves as a guest reviewer for several journals.

Dr. Barakat’s major focus is on developing and applying state-of-the-art computational drug discovery tools to discover new antiviral and immunotherapeutic drugs.

Dr Nguyen Van Bang finished his PhD in Amiens University, France in 2005 and has awarded Associate Professor in 2009 and becomes Executive Member of Vietnam Pediatric Association and Vice-President of Vietnam Pediatric Digestive Association since 2010. He is director of an international scientific project (origin of the proposed communication), of 2 national and 3 ministerial ones and numerous hospital and community based studies. He has published more than 100 scientific papers in reputed international and national journals in medicine and healthcare (5 in French, 7 in English and more than 90 in Vietnam). He has presented more than 20 communications in world and international congresses.

Medicine and Healthcare

Dr. Patricia Araujo received her Ph.D. from the University of Cambridge (UK) and was a post-doctoral fellow in the Molecular Virology Department at the Federal São Paulo University (Brasil).

She is now an Chief of Virology and Serologic screen laboratories at the Blood Bank- Colsan of Federal São Paulo University.She has a long standing interest in the molecular biololgy of hepatitis B virus, mechanisms of virus replication and virus host cells interactions that result in innate immune responses to infection.

Dr Massimo Cecaro after completing the high school in humanistic studies, he moved to the University of Camerino, where he got a Master Degree in Veterinary Medicine and in University of Teramo he successfully got the Specialization. Since the age of 14, he has worked as radio speaker, tv presenter and reporter for a wide range of artistic and scientific events. At the age of 24 he obtained a qualification to practice as a Journalist and in 2007 he was admitted to the National Association of Medical Press (ASMI), where he currently hold the position of National Councilor. He is Resident Member of MJA Medical Journalists’ Association (London). He is Member of EFSA's Expert Database. He has been an invited speaker,mentor and chairman at International events in the field of Public Health and Safety in Canada, US, Europe and Asia. He has been author of several scientific works in public health. He is also director in Italy of a prestigious Educational Centre for work safety and public health. He is actively involved in international projects to improve the role of mass-media in medical sciences, and awarded in Philadelphia, Valencia and Las Vegas with International special recognition. He is serving as an editorial member of several reputed journals like: “Journal Food Processing Technology”, “Journal of Veterinary Science & Technology”, and Editor in Chief in the “Occupational Medicine & Health Affairs” and in “Journal of Mass Communication”. He is Reviewer for "Journal od Cancer Science & Therapy”. He is Organizing Commette Member of several International Conferences in US and in Europe

• Medical and scientific communication • Risk analysis • Epidemiology • Work safety • Food safety • Nutritional Science • Anthropozoonoses • Comparative oncology

Paul B.Fisher is Professor & Chairman, Department of Human and Molecular Genetics and Director, VCU Institute of molecular Medicine, Virginia Commonwealth University School Of medicine ,Richmond , Virginia, Research focuses on three broad areas; cancer, neurodegeneration & infectious diseases. A primary aim is to move discoveries made in the laboratory into the clinic, the concept of “bench-to-bedside”. He is among the top 5% of NIH funded investigators over the past 25 years, published over 400 primary papers and review articles, serves on many US government and private review panels and has over 55 issued US and numerous international patents.

Innovative approaches to discovery and molecular characterization of genes involved in susceptibility to cancer, neurodegeneration and infectious diseases.

Dr. Babita Agrawal is a professor in the Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. She completed M.Sc. (1987) in biochemistry and PhD (1993) in Immunology. After completing post-doctoral work, she joined a major Canadian biotech company in 1996 where she received outstanding R & D achievement awards for consecutive years and rose to the position of Manager and Head of Immunology Research. She headed a large group of scientists, focusing on basic to translational research on novel immunotherapy and vaccine technologies, leading to clinical trials. In 2001, she joined the University of Alberta as an assistant professor and received a Medical Scholar Award in 2002 from the Alberta Heritage Foundation for Medical Research (AHFMR). In 2007, she was promoted to the rank of associate professor with tenure. In the same year she obtained a Senior Scholar Award from the Alberta Innovates Health Solutions (AIHS). In 2011, she was honored by Dean’s Award in the Faculty of Medicine and Dentistry, U of Alberta. In 2013, she was promoted to full professor. She is an established investigator with proven leadership in immunotherapy and vaccine research. In addition to a number of provincial and national grant committees, she has served as an external scientific expert in cellular immunology and vaccine research on NIH and NCI, U.S.A., grant panels and site visits.

Her research focuses on studying immune regulation and innate and adaptive immune responses, and novel small molecule inhibitors against viral infections and cancer, in order to design and study novel vaccine, immuno- and chemo-therapeutic strategies. She has published several pioneering papers in the field and has a number of issued patents. Recently, she has co-founded a small biotech based on her research in the areas of vaccine and therapeutics.

Dr.A.K.Prasad is the currently working as President of Indian Virological Society.He is also the chairman of Influenza Foundation of India.He was elected Fellow of the Geriatric Society of India (FGSI) 2014 at their Nagpur Convention (8-9 November, 2014).He has also Published over 60 Research Papers in national & International Journals & 3 Books (Chapter on Influenza).He has also received Life Time Achievement Award conferred by the Geriatric Society of India on 06th November, 2014 at the Vaccine Advocacy for the S E Asian Countries held at Delhi.

Influenza Research

Dr Atmaram Bandivdekar completed his Ph D Degree at the age of 31 years from Mumbai University. Bandivdekar was the Post-Doctoral and Carrier fellow at Population Council, New York. He was also the visiting scientist at UC Davis Primate Center. He is the Deputy Director of National Institute for Research in Reproductive Health which is the premier Institute in India in the field of Reproductive Health Research. He has published more than 70 papers in peer reviewed journals and also the book and two conference proceedings. He also has six National and International awards for his scientific contributions. Bandivdekar is actively involved research on understanding sexual transmission of HIV and development of preventive and therapeutic vaccine and formulation for prevention of HIV transmission.

Research on Viruses.

Dr. Hemida received his Ph.D from University of Guelph, 2009. He pursued his PDF training at the the University of British Columbia (James Hogg iCapture Centre). His research area of interest is “One Health Concept” with special emphasis on emerging viruses/host interaction. Currently, studying the molecular evolution and pathogenesis of MERSCoV in the Middle East. He published more than 40 original Research papers on high impacted journals. Meanwhile, he received several Research grants, prestigious honors and scholarship throughout his academic carrier. Currently, he is a reviewer of many granting agencies as well as editorial board member of many international journals.

Research interest on MERS.

Dr Benani is a responsible of Molecular Biology Laboratory at Pasteur Institute of Morocco this laboratory is a national reference laboratory for Hepatitis C Program (Moroccan ministry of health). He is also the elect-president of Arab Society for Virology and Active member on the Advisory Board, Consultative Meeting on Regional Strategy for Prevention and Control of Viral Hepatitis and Other Epidemics-Prone Blood-Borne Diseases, in 2008 (WHO/EMRO, Cairo, Egypt). He got his master of molecular biology and biotechnology at Université Libre of Bruxelles (ULB, Belgium) and his PhD in molecular microbiology in Fes University (Morocco). He participates in several international and national workshops and congresses. He is also implicated in student’s research for their training, master, and PhD. He published in several journals including journal of medical virology, BMC public health, Virology Journal, He is an active researcher in molecular epidemiology of HBV and HCV in general population and high Risk groups in Morocco. He organized the 1st International Symposium for Virology in Morocco in 2003 (Marrakech, Morocco) and the First PCR Forum and Molecular Typing at Pasteur Institute of Morocco

Molecular epidemiology of HBV and HCV

Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Law”, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem” for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.

Virology

Sevgi Ciftci is the Associate Professor at the the Department of Microbiology, Faculty of Dentistry, Istanbul University, Turkey. Dr. Sevgi Ciftci obtained her BA in department of the medical biological sciences in Faculty of Medicine from the Dokuz Eylül University at Izmir- Turkey, and her PhD in Microbiology from the Medical Faculty of Istanbul University at Istanbul, in 2003.

Virology

Robin J Green is Director of Paediatric Services and Paediatric Pulmonology, Paediatric Intensive Care and Allergy Services at the Steve Biko Academic Hospital, Pretoria. He is a Full Professor in the Department of Paediatrics and Child Health within the School of Medicine at the University of Pretoria. He holds a PhD and DSc, and is a fellow of the Royal College of Physicians and Past President of the College of Paediatricians of South Africa. He is also Immediate Past Chairman of the Allergy Society of South Africa. The National Research Foundation rates him as an established researcher, in paediatric pulmonology.

Paediatrics and Child Health

Edgar Marcelino de Carvalho Filho was born in Salvador, Bahia, on May 24, 1950. His parents, Edgar Marcelino de Carvalho and Valdemira Silva de Carvalho, were teachers, had teaching activities and were an example and a stimulus for the son. The secondary course was held at the Colégio AplicÃo of the Federal University of Bahia, one of the best schools in Salvador and recognized as a teacher of student leaders. The interest in medicine and teaching comes from childhood and adolescence and interest in research during the medical course at the Faculty of Medicine of the Federal University of Bahia. APSA graduation in 1973 made residence and Masters in Internal Medicine and in 1977 held fellowship in the area of Immunology and Rheumatology at the University of Virginia. The Master's thesis entitled "Patients with Bacteremia in severe strongyloidase The importance of the worm as a vehicle or synergistic agent of bacterial infection" was guided by Professor Heonir Rocha, a researcher who also directed several scientific works At the beginning of the career. The training in Immunology at the University of Virginia was conducted with Dr. David Horowitz, having been useful in relation to the learning of immunology techniques as a proficiency in scientific productivity stay. In this period they were published three manuscripts in J. Immunol. and in Clin. Exp. Immunol. . Immunology did not yet exist in Bahia when he returned in 1979, when he created the Research Laboratory in Immunology, which later was elevated to the category of Immunology Service. It was at this time that interest in leishmaniasis began, which together with schistosomiasis and strongyloidase constitute the main lines of research of the Immunology Service. He defended his doctorate in 1986 with the thesis "Cellular Immunity in Visceral Leishmaniasis", on which occasion he became an Adjunct Professor of the Faculty of Medicine of the Federal University of Bahia. He coordinated for four years the P s-Graduation course in Internal Medicine of the Federal University of Bahia and coordinates until the moment (2002) the activities of masters and doctorate in the area of Clinical Immunology. J directed 17 master's theses and 8 doctoral theses and at the moment 2 master's degrees and 7 doctoral students are under his guidance. The main lines of research are the Immunology of Visceral and Intestinal Leishmaniasis, Immunotherapy in Infectious Diseases, Immunoregulation in Mansonic Schistosomiasis and Clinical and Immunological Aspects of the Association between HTLV-1 and Strongyloidase. J was a member of the editorial board of the Brazilian Journal of Medicine and Biological Research and Associate Editor of the Journal of the Brazilian Society of Tropical Medicine. member of the Brazilian Society of Immunology, organ presided between 1989 and 1991, the American Association of immunologists , the Brazilian Society of Tropical Medicine and the American Journal of Tropical Medicine and Hygiene .

Immunology of tegumentary leishmaniasis. Clinical and therapeutic aspects of tegumentary leishmaniasis. Natural history and immune response in HTLV-1 infection. Association between HTLV-1 infection and helminthiasis. Immunomodulation in schistosomiasis.

Harold C. Smith, Ph.D. is a cell and molecular biologist and tenured full professor in the Department of Biochemistry and Biophysics at the University of Rochester, School of Medicine and Dentistry. As a member of the faculty, Dr. Smith developed and instructs the primary technical training course for undergraduates in the Biochemistry major and runs a research laboratory from which over 130 pier reviewed publications have emerged on biological control mechanisms affecting diseases such as cancer, elevated cholesterol and heart disease and HIV/AIDS. He has led his research field with federal and foundation funding and is a key opinion leader on APOBEC host defense factors. In 2003, Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry. OyaGen is located at 77 Ridgeland Rd in Henrietta NY, USA. For more information on Dr. Smith and OyaGen please visit the following webpages: http://en.wikipedia.org/wiki/Harold_Smith_(scientist) http://www.oyageninc.com

Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry.

Dr. Julius Nwobegahay was born in Cameroon. He Obtained a Bsc (Hons) Microbiology degree at the University of Calabar, Nigeria; a Masters degree in Virology at the University of Ibadan, Nigeria; and a Doctoral degree (topic: ‘Human Immunodeficiency Virus Genetic Drug Resistance and Subtype Distribution in Northern South Africa’) from the University of Venda, South Africa. He has authored and co-authored many scientific publications in peer reviewed accredited national and international journals, and have presented papers at international conferences in South Africa and Europe. He is also a reviewer for many scientific journals, and has mentored and supervised many graduate students. He is presently the head of the Military Health Research Center (CRESAR) in Cameroon. Dr. Nwobegahay’s laboratory is actively involved in research on military medical research ethics and guidelines, human subject research with military populations, HIV drug resistance, Hepatitis B and C viruses. Furthermore, CRESAR is collaborating with its main partner - Metabiota Cameroon to roll out programs within the Cameroon military on HIV/AIDS prevention; reinforcement of prevention of mother-to-child transmission (PMTCT) of HIV; boosting the laboratory capacities of Cameroon military health formations; rapid detection, response and research on avian influenza, monkey pox virus, etc.

Ethics in military medical research; HIV/AIDS; HIV drug resistance; HBV; HCV; phylogenetics.

Enzo Tramontano holds a degree from the University of Cagliari (1990), he was Visiting Research Scientist at the Dept. of Pharmacology at Yale University Medical School (CT, USA, 1990-1992 and 1996-1998). He was given two post-doctoral awards granted by the Istituto Superiore di Sanità for “Research in the HIV field: AIDS Project”, for research activities performed in national (1993-1995) and international (1996-1998) institutions. Since 1998 he has worked at the Departments of Experimental Biology (1998-2003), Biomedical Sciences and Technologies (2003-2007), Applied Sciences in Biosystems (2007-2010) and Life and Environmental Sciences (2011-2012) at the University of Cagliari being appointed as Research Associate (1998), Assistant Professor (2001), and Associate Professor (2006). He is now responsible for the Biomedical Section of the Department of Life and Environmental Sciences of the University of Cagliari. He is member of the European Society of Virology, the International Society for Antiviral Research, the Italian Society of Virology and the Italian Society of General Microbiology and Microbial Biotechnologies. Prof. Tramontano serves as ad hoc reviewer for several International Journals and the Italian Minister of Research.

-

Dr. Barr obtained his PhD in Molecular Biology from the University of Calgary, studying a family of antioxidant proteins called Peroxiredoxins in the tropical parasite called Leishmania. His research provided a better understanding of how intracellular pathogens such as Leishmania survive inside of macrophages, which are the cells normally designed to kill these pathogens. After his PhD, Dr. Barr traveled to Philadelphia as a Postdoctoral Fellow to work with Dr. Rick Bushman at The University of Pennsylvania. There he studied the molecular interactions between the human immunodeficiency virus (HIV) and host cellular genomes. His research provided a better understanding of how HIV permantently integrates into the genome of its host cells; a process that contributes to life-long infection. Near the end of his time with Dr. Bushman, he discovered a novel human protein called TRIM22 that inhibits HIV replication by trapping the virus inside of cells. He took this project to the laboratory of Dr. Smiley at the University of Alberta to utilize the expertise of Dr. Jim Smiley to better understand the mechanism of how TRIM22 traps HIV inside of cells. Near the end of his time in Dr. Smiley’s laboratory he discovered another novel human protein called HERC5 that also inhibited HIV replication. Dr. Barr took this project to Western as an independent investigator where his team unlocked the novel mechanisms by which this interesting protein blocks HIV replication. Currently, Dr. Barr is a molecular virologist at Western in the department of Microbiology and Immunology where his team continues to unlock the mysteries of TRIM22, HERC5 and HIV. It is their goal to exploit the powerful and natural activities of HERC5 and TRIM22 to help block HIV replication and allow our immune system to get the upperhand in clearing HIV infection. Dr. Barr’s team also recently discovered an exciting new way that HIV integrates into the human genome. This research hopes to uncover a neverbefore seen mechanism of how HIV establishes and maintains latency, which is one of the biggest obstacles in curing HIV/AIDS. Their work also has potential implications in the design of next-generation retroviral-based gene therapy vectors.

-

The Gabonese researcher, Donatien Mavoungou, is about to discover the first vaccine against the AIDS virus. The professor in chemistry worked out IMMUNOREX TM which test results are rather promising for the moment. During his passage on 16th June 2014 in Libreville (Gabon), Pr Donatien Mavoungou and his colleagues presented to the Gabonese press, IMMUNOREX TM, the treatment that could become the vaccine against the HIV / AIDS. According to the Gabonese quoted by the site Gabonreview, the vaccine is tested at its second phase and was already tested on 200 sick people in France without any negative reaction registered. “We have at present a therapeutic vaccine against AIDS, which is till today, one of the rare in the world to have succeeded to enter into the 2nd phase with an authorization of stopping the triple agent therapy for two months“, declared Pr Mavoungou. The Gabonese researcher is supported in his works by the managing director of the international institute for developement and the support innovative scientific research, Michel Paul Correa. For the latter, “involving Gabon via Immunorex of Pr Donatien Mavoungou in the development of a vaccine against AIDS with Biosantech is an important challenge in all respects for the influence of Gabon.” Africa is the continent the most affected by the HIV / AIDS. In 2005 UNAIDS registered 1,8 million deaths caused by the virus on the continent.

HIV / AIDS, Virus, Vaccines

Eddy Arnold is Board of Governors Professor of Chemistry and Chemical Biology at Rutgers University and a Resident Faculty Member at the Center for Advanced Biotechnology and Medicine. He has authored more the 240 scientific publications. Among his awards and honors are two NIH MERIT Awards (1998-2008, 2009-2019) and the Hyacinth Award “Honoring Advances in the Struggle Against AIDS” (2013). He is an elected Fellow of the American Association for the Advancement of Science (2001) and in the American Academy of Microbiology (2006).

-

Ekwu B. B. Ochigbo is a Registered Pharmacist and an HIV & AIDS resource person. He holds an M. Phil. with distinction in HIV & AIDS Management from the Africa Centre for HIV & AIDS Management, Stellenbosch University, Cape Town, South Africa. He is also the Director of Tibe Pharmacare, a pharmaceutical and health research consultancy close corporation. His interests are in therapeutics and treatment outcomes research. Ochigbo has participated in different clinical research including the pharmacokinetics study for Boehringer Ingelheim- 1100.1518, an open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of Nevirapine extended release tablets in HIV-1 infected children, leading to the successful registration of Nevirapine XR by the USA FDA in March 2011. He was also Principal Investigator for the study of the Adherence to prevention of mother to child transmission (PMTCT) therapy among HIV infected pregnant women in Area W Clinic, Botswana. Ochigbo is a member of the Pharmaceutical Society of Nigeria, the Pharmaceutical Society of Botswana, and the Pharmaceutical Society of Namibia. He is also a member of the Rotary club of Francistown.

-

Vladimir Zajac has completed his Ph.D. in 1982 at the Cancer Research Institute of Slovak Academy of Sciences in Bratislava (Slovakia), where he was from 1996 to 2010 the Head of Department of Cancer Genetics. He joined the Medical Faculty of the Comenius University as Associate Professor of Genetics in 2007. He has published 56 papers mostly in reputed journals and he was editor of the book "Bacteria, viruses and parasites in AIDS process" (InTech)

Cancer and AIDS

Dr. Lindsay Hughes is a behavioral scientist with 10 years of progressive experience in research, design, proposal development, and implementation of evidence-based health science studies and interventions using effective, strategic, and culturally sensitive human communication and information technologies to improve health outcomes through increased access and adherence to medical interventions. She has developed various models to measure patient outcomes at the individual, dyadic, and community levels, and has designed innovative dissemination and data capture tools using eHealth and mHealth platforms.

Dr. Hughes has extensive experience managing concurrent diverse, multi-faceted domestic and international OR portfolios in various capacities (including PI, AI, and Advisor); partnering with clinical and laboratory scientists; and capacity building and mentorship of junior staff and scientists as well as local and indigenous organizations to improve scientific acumen, and leverage resources to develop strategic partnerships with governments, ministries, and private-sector partners. She has worked with various funders (e.g., USAID, CIDA, CDC, NIH, DOD, WRAIR, BMGF, HRA Pharma) and has a track record of developing, facilitating, and improving relationships with clients and stakeholders. She is skilled at quantitative and qualitative methods; regulatory strategy design; scientific, consulting, and technical writing; and translation of data for diverse audiences.

Karin Moelling was born in Northern Germany, trained as a physicist specialized in Nuclear Physics. She was trained at Berkeley, University of California, in Molecular Biology and Biochemistry. She took her PhD at the Max-Planck-Institute for Virology at Tübingen, Germany, and her Habilitation at the University of Giessen in Biophysics. She worked at the Robert Koch-Institute in Berlin, the Max-Planck-Institute for Molecular Genetics in Berlin. In 1993 she became Director and Professor of the Institute for Medical Virology at the University of Zurich and Head of the Viral Diagnostics Department of the University Hospital, which she increased 15-fold. She had to retire there and is still affiliated with the University of Zurich and the Max-Planck-Institute for Molecular Genetics in Berlin. She was Fellow at the Institute of Advanced Study at Berlin 2008/2009 and became Vice President of the Fellow Club.

Viruses, in particular retroviruses, and cancer, from molecular mechanisms to drug design. Replication of HIV, discovery of the retroviral RNase H, development of antiretroviral mechanisms driving HIV into suicide, and various oncogenes such as identification of Myc and Myb as nuclear transcription factors, and discovery of the Mil/Raf kinase as retroviral oncogene. Interest in signal transduction in normal and tumor cells, gene regulation, cell-cycle, transcription factors, PDZ domains, scaffold proteins, oncogenes in leukemias, lymphomas, cancer, gene medicine/therapy, vaccines, HIV/AIDS, Influenza, viruses in immune-suppression, antiviral drug design, silencing by siDNA. biotechnology, non-coding RNA, endogenous viruses, evolution of viruses.

Specialty: Viral Oncology Awards Research Career Award National Research Council of Argentina Damon Runyon Fund Fellowship Member National Academy of Medicine, Argentina
Outstanding Women in Science Award AWIS Metropolitan N.Y Fellow New York Academy of Sciences Membership Sigma Xi, The Scientific Research Society

The main research of this laboratory concerns molecular mechanisms of viral pathogenesis. Fifteen percent of human cancers are associated with or caused by viruses. We are investigating if a virus similar to the mouse mammary tumor virus (MMTV) is involved in human breast cancer pathogenesis. We have found viral sequences similar to MMTV in 38% of the human breast cancers tested. They were expressed as RNA and proteins. A complete proviral structure has been detected with the characteristics of a replicative competent virus. Recently, we isolated and characterized a beta retrovirus from primary cultures of human breast cancer cells. The retrovirus is able to infect epithelial and lymphocytic human cells. Its potential for malignant transformation is being investigated. Epidemiological studies on breast cancer and retroviral incidence are also carried out by analyzing samples from different geographical locations. The transcriptional profile of breast cancer cells carrying the virus was also investigated. Together, these studies will help to determine if a retrovirus is involved in human breast cancer pathogenesis.

Dr. Shan Cen is a Professor and Head of Immunology Division at the Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Pekin Union Medical College, China, Project director, Lady Davis Institute for Medical Research, Jewish General Hospital Canada, Adjunct Assistant Professor Department of Microbiology, McGill University, Canada, Adjunct Faculty member Department of Medicine McGill University, Canada. He received his PhD degree in Microbiology from Chinese Academy of Preventive Medicine in 1994. He has completed his MS in Microbiological Medicine, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, China, and he has also completed BSc from the Department of Microbiology, Shandong University, China. Dr Shan Cen has been serving as a reviewer for reputed journals including J Biol Chem J Virol PlosOne Virology Retrovirology for years.

Virus-host interaction, Host restriction factor, Viral assembly, Reverse transcription, Novel antiviral target, Establishment and validation of drug screening assay, HIV, HCV, Influenza, EV71.

Dr. Mansky is Professor and Director of the Institute for Molecular Virology, University of Minnesota. He received his PhD degree in Molecular Virology from Iowa State University and was a postdoctoral fellow in the laboratory of Dr. Howard Temin at the McArdle Laboratory for Cancer Research, University of Wisconsin-Madison.

Cell and molecular biology of HIV and HTLV; HIV drug resistance; HTLV particle assembly and release; Evolution of emerging viruses

Huynh has received Ph.D. in Bio-Organic chemistry from the University of Tokyo, Japan, in 1979. He was chemist at Nippon Kayaku Chemical Co. Japan and postdoc with School of Pharmacy, Purdue University. He worked with Stanford Research Institute International, in Bio-Organic Chemistry Department, and Applied Biosystems Inc., in R&D Department. Huynh was senior manager in anti-HIV research at Triplex Pharmaceuticals Inc., and molecular diagnostic research at Gen-Probe Inc. From 2009, he worked as CSO of Genomeplex Research Institute, Inc. for manufacturing of Real Time PCR for HIV-1 virus. He has more than 200 presentations, publications and product developments with companies.

Andrew D. Badley, M.D., was born in Sydney, Nova Scotia, Canada. He earned his B.S. degree in 1985 and M.D. degree in 1990, both from Dalhousie University in Halifax, Nova Scotia. After completing residency training in internal medicine at Mayo Clinic in Rochester, Minn., in 1994, Dr. Badley completed further training at Mayo Clinic as a clinician investigator trainee in the Division of Infectious Diseases in 1997. During his training, Dr. Badley received the Dr. J. Geraci Award for Excellence in Infectious Diseases from Mayo Clinic in June 1997, as well as the Young Investigator Award from the Interscience Conference on Antimicrobial Agents and Chemotherapy and American Society for Microbiology (ICAAC/ASM) in September 1997. Dr. Badley joined the staff of Ottawa Hospital in Ottawa, Ontario, Canada, in 1997 as an assistant professor in the Division of Infectious Diseases and in 2002 was promoted to an associate professor. In 2002, Dr. Badley returned to Mayo Clinic in Rochester as a consultant in the Division of Infectious Diseases and brought with him his successful research program. At Mayo Clinic, Dr. Badley is currently a professor of medicine and consultant in the Division of Infectious Diseases; associate director of the Research Resources component of the Center for Translational Science Activities; and theme leader for infectious disease research on the Research Development Council, an internal Mayo committee.

virus-host interactions, in particular how viral proteins modify the host immune response and/or cell survival.

erthold Kepplinger was medical director of the neuro-rehabilitation Wall Amstetten and the Neuro Rehabilitation and Pain Wall Amstetten and Head of acute Logie and Stroke Unit. In the past 10 years, he worked as medical director of the State Hospital Wall Amstetten.

Baran Halina is presently Head of the Karl Landsteiner Research Institute for Neurochemistry, Neuropharmacology, Neurorehabilitation and Pain Treatment Mauer, Lower Austria, From 2005 - 2011 she was the head of Head of the Neurochemical Laboratory Karl Landsteiner Institute Mauer and Head of Neurophysiology, Veterinary Medical University Vienna.

Francois Villinger, DVM, PhD, Chief of the Yerkes Division of Pathology, graduated from the University of Zurich, Switzerland. The primary research interests of Dr. Villinger and his lab team are modeling human infectious diseases in relevant nonhuman primate models, particularly for those diseases without other models and those that do not reproduce human pathogenesis. These diseases include HIV/AIDS as well as infection models of XMRV, dengue fever and listeria. As Chief of the Division of Pathology, Dr. Villinger oversees the administrative functions of the division. This entails oversight of the administrative staff, approving grant submissions by division faculty and trainees, ensuring appropriate allocation of division resources and mentoring junior faculty. Dr. Villinger is involved in reporting division research activities to the National Center for Research Resources (NCRR) and preparing progress and plan descriptions of division research activities for the Yerkes Research Center’s P51 base grant renewal. Dr. Villinger also serves as the liaison between division staff and the Yerkes administration, and advises the director on issues related to the scientific mission of the Center. In addition, the Villinger lab runs a NCRR-funded resource that provides nonhuman primate specific immunomodulatory reagents, such as recombinant cytokines and soluble forms of immune-receptors, to investigators on a national and international level. The Yerkes research center provides 60 samples annually.

Immunology of infectious diseases, AIDS and resource for nonhuman primate immune reagents.

Stela Halichidis is a director in the Department of Medical Faculty at Ovidius University, Romania. She was head of HIV department, Constanta, Romania. She has published various papers related to HIV, and is member in many national and international medical associations (ESCMID, ESC, Romanian Infectious Diseases Society, Balcanic Medical Society, Romanian Parasitology Society, International AIDS Society, and Balkan Environmental Association).

Daniel Bauer is internationally revered as theSuccessor to the legendary escape artist Harry Houdini and globally respected as a 12-year warrior and survivor living with HIV/AIDS.Through heart-breaking loss, such as burying his baby brother who passed from AIDS-related complications, to conquering impossible moments of rare survival, Daniel Bauer has gracefully triumphed to once again pursing his dreams. Daniel Bauer is one the most requested motivational public speakers and entertainers who continues to present highly engagingeducational experiences and spectacularly, life-changing theatrical productions to tens of thousands annually(adolescents, healthcare professionals and mainstream communities &audiences at-large)focusing on topics such as living with HIV/AIDS, prevention, reversing HIV/AIDS-related man-made stigma and so much more. Daniel Bauer is the current active celebrity voice and face of JustGetTested.com. He continues to work tirelesslyto promote equality for all living with and/or affected by the global HIV/AIDS pandemic. His work as both an escape artist and speaker have been featured on: National Television Networks [NBC, CBS, ABC and FOX], International print/radio media (i.e. poz.com/blogs, positivelite.com, NPR Radio, Poz I Am Radio Show),International Theatrical Stages including New York City’s off-Broadway; and has been highlighted at internationally revered events such as The OMICS Group2013 International HIV/STI Conference, The National Healthy Living Summit, 2012 International AIDS Conference (AIDS Reunion Program, Washington, D.C.), The 2013 University of Minnesota African Student Association Red Spots Gala, and The Texas State-wide HIV/HEI Conference. And if that is not enough of an iconic ship of accomplishment, Bauer has also held prime consulting and contractual professional positions in the fields of government, education, special event planning, fund raising and youth development programming to promote healthy-living and equality for all walks of life while continuing to create waves, inspire hope and promote positive change among our communities to unite global synergistic efforts in the fight against HIV/AIDS.

Design and analysis of clinical trials for vaccines against infectious diseases, Statistical methods in immunological assay validation and evaluation, Statistical methods in equivalence testing, Immune correlates of protection and Meta-analysis.

Dr. Aboul-Ata Elnady ABOUL-ATA, Professor Dr. of Plant virology, who was born on Mar.22nd 1948 in Sharkia, Egypt, is the president of ArSV (Arab Society for Virology) in 2013. He was formerly Department Head of Plant Virus and Phytoplasma Research, Plant Pathology Research Institute at Agricultural Research Center, Giza, Egypt for 3 years (2003-2006), and Head of Molecular laboratory at Plant Virus and Phytoplasma Res. from Sep. 2005 up to now. Dr. Aboul-Ata is the author of more than 40 scientific papers in different approaches like gene silencing, sequencing of viral genes. He lead an Egyptian research group (human virologists and molecular biologists) for a Swedish-funded project on Plant-based vaccine against HSV-2 in collaboration with Gothenburg University, Sweden throughout 2007-2010. He also lead a MERC project on detection of cereal viruses for prevention through quarantine system in Middle East countries (Egypt, Jordan, Israel and Palestine) throughout 2008-2011. He is in charge of nanoscience introduction to the domain of plant virology at Plant Pathology Research Institute. He is chosen for general-, scientific- and organizing-committee member for the First and 2nd Conference of Virology, which was organized by ESV at 2004 and 2008, Cairo, Egypt. He has also been chosen to be International Advisory-committee member for the 2nd Green revolution in India that is organized from 2-5 July, 2009. He is an evaluation-committee member for promotion to higher scientific position i.e. Assoc. Professorship and Professorship at Institute of Plant Pathology, ARC, Egypt 2008 up to now.

Dr. Nafees Ahmad received his B. S.(Hons) in Chemistry and M. S. in Biochemistry from one of the prestigious central universities in India, The Aligarh Muslim University. He then joined another renowned research institute, The Central Drug Research Institute, Lucknow, India, from where he earned his Ph.D. in 1983. Dr. Ahmad did his Postdoctoral Fellowship at the National Institutes of Health (NIH), Bethesda, Maryland, USA from 1985-1990 in the Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases. His research primarily focused on the regulation of HIV-1 gene expression and replication, especially the role of HIV-1 regulatory and accessory proteins in HIV-1 replication and biology. In 1990, a group of scientists from the NIH, including Dr. Ahmad moved to J.N. Gamble Institute of Medical Research, Cincinnati, Ohio to start a new program on Molecular Virology, including his own independent research program on molecular mechanisms of HIV-1 mother-to-infant transmission. In 1994, Dr. Ahmad joined the University of Arizona College of Medicine’s Department of Microbiology and Immunology (now Immunobiology). His research involves understanding the molecular mechanisms of differential HIV infection in infants and adults and vertical transmission and pathogenesis. In addition, he directs the Immunity and Infection block of the medical curriculum of the College of Medicine.

Dr. Ramendra K. Singh, an Associate Professor of Chemistry at the University of Allahabad, India, is Director of the Nucleic Acids Chemistry and Antiviral Research laboratory and is member of several national committees. He has several awards/fellowships, like ISCA Young Scientists Award, INSA Visiting Fellowship, UNESCO Fellowship, XVI IUBMB Fellowship, Jawaharlal Nehru Visiting Fellowship, Post-Doc Fellowship, Govt of Japan, INSA International Exchange Fellowship and Fulbright-Nehru Senior Research Fellowship to his credit. His research interest lies in computer-aided designing and development of antiviral molecules against HIV, HPV and JEV and developing fluorescent oligonucleotides for use in the field of molecular biology and diagnostics. He has about a dozen anti-HIV and half-a-dozen anti-JEV compounds under patent processing. Dr. Singh is on editorial board of several international journals and referee to more than a dozen journals.

Heather initially completed her BS in Biology at the University of North Carolina, Chapel Hill, moving on to study for an MD/PhD in Molecular and Cell Biology at Tulane University, New Orleans, qualifying in 1999. She currently is a Senior Scientist at Seattle Biomed and a Senior Lecturer at University of Cape Town. She also holds an affiliate Associate Professorship at University of Washington’s Department of Global Health.

prevention of HIV acquisition in children and adolescents and immunology thereof.